Print
Save
Email this link

Share Link

Copy this link, or click below to email it to a friend
Email this link
or copy the link directly:

https://ec.bioscientifica.com/search?f_0=author&q_0=Sarah+M+Creighton
The link was not copied. Your current browser may not support copying via this button.

Link copied successfully

Search Results

You are looking at 1 - 1 of 1 items for

Author: Sarah M Creighton x

Clear All Modify Search

Hormone replacement treatment choices in complete androgen insensitivity syndrome: an audit of an adult clinic

Jennifer K Y Ko

Jennifer K Y Ko Department of Women’s Health, University College London Hospital, London, UK

Search for other papers by Jennifer K Y Ko in
Google Scholar
PubMed

Thomas F J King

Thomas F J King Department of Women’s Health, University College London Hospital, London, UK

Search for other papers by Thomas F J King in
Google Scholar
PubMed

Louise Williams

Louise Williams Department of Women’s Health, University College London Hospital, London, UK

Search for other papers by Louise Williams in
Google Scholar
PubMed

Sarah M Creighton

Sarah M Creighton Department of Women’s Health, University College London Hospital, London, UK

Search for other papers by Sarah M Creighton in
Google Scholar
PubMed

, and

Gerard S Conway

Gerard S Conway Department of Women’s Health, University College London Hospital, London, UK

Search for other papers by Gerard S Conway in
Google Scholar
PubMed

Objective

To review the treatment choices of women with complete androgen insensitivity syndrome (CAIS) at a single tertiary centre.

Design

Retrospective review.

Patients

Women with CAIS identified from our database.

Results

The study group comprised 141 women with CAIS. Eleven percent (16/141) of women had gonads in situ, 3 of whom were under workup for gonadectomy. The age of gonadectomy in the remainder 125 women was 17 (0.1–53) years. The most common form of HRT was oral oestrogen or transdermal oestrogen in 80% (113/141). 13/141 (9%) women used vaginal oestrogens alone or together with other forms of HRT. Testosterone preparations had been used by 17% (24/141) of women and were currently used in 10% (14/141). Of those who had used testosterone, 42% (10/24) had chosen not to continue after a therapeutic trial.

Conclusions

In a clinic offering individualised multidisciplinary care for women with CAIS, we found that the majority of women chose oestrogen-based treatment while a significant minority used testosterone.